- Home
- EDSA vs INDP Comparison
EDSA vs INDP Comparison
Compare EDSA & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- INDP
- Stock Information
- Founded
- EDSA 2015
- INDP 2000
- Country
- EDSA Canada
- INDP United States
- Employees
- EDSA N/A
- INDP N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- INDP Health Care
- Exchange
- EDSA Nasdaq
- INDP Nasdaq
- Market Cap
- EDSA 6.2M
- INDP 7.4M
- IPO Year
- EDSA N/A
- INDP N/A
- Fundamental
- Price
- EDSA $2.36
- INDP $0.47
- Analyst Decision
- EDSA Strong Buy
- INDP Strong Buy
- Analyst Count
- EDSA 1
- INDP 2
- Target Price
- EDSA $21.00
- INDP $8.50
- AVG Volume (30 Days)
- EDSA 8.9K
- INDP 71.0K
- Earning Date
- EDSA 05-09-2025
- INDP 05-07-2025
- Dividend Yield
- EDSA N/A
- INDP N/A
- EPS Growth
- EDSA N/A
- INDP N/A
- EPS
- EDSA N/A
- INDP N/A
- Revenue
- EDSA N/A
- INDP N/A
- Revenue This Year
- EDSA N/A
- INDP N/A
- Revenue Next Year
- EDSA N/A
- INDP N/A
- P/E Ratio
- EDSA N/A
- INDP N/A
- Revenue Growth
- EDSA N/A
- INDP N/A
- 52 Week Low
- EDSA $1.55
- INDP $0.43
- 52 Week High
- EDSA $5.59
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- EDSA 51.83
- INDP 36.28
- Support Level
- EDSA $2.29
- INDP $0.45
- Resistance Level
- EDSA $2.40
- INDP $0.53
- Average True Range (ATR)
- EDSA 0.12
- INDP 0.04
- MACD
- EDSA 0.00
- INDP 0.01
- Stochastic Oscillator
- EDSA 87.88
- INDP 41.41
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.